Latest & greatest articles for spironolactone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on spironolactone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on spironolactone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for spironolactone

1. Spironolactone is effective for treating resistant hypertension

Spironolactone is effective for treating resistant hypertension Signal - Spironolactone is effective for treating resistant hypertension Dissemination Centre Discover Portal NIHR DC Discover Spironolactone is effective for treating resistant hypertension Published on 1 December 2015 This trial investigated which drug is best added to high blood pressure (hypertension) treatment if blood pressure has not come down to normal levels after taking three blood pressure lowering drugs. Such “resistant (...) hypertension” accounts for around 10% of all people who have hypertension. The study found that adding spironolactone to the existing three-drug regimen was the most effective treatment and was well-tolerated by patients. Spironolactone is currently recommended by NICE at this fourth stage of treatment, but at half the dose used in this study. The higher dose will increase the cost of prescribing slightly. Potassium levels need to be monitored when using spironolactone as there is a risk they can rise

2018 NIHR Dissemination Centre

2. Spironolactone

Spironolactone Top results for spironolactone - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for spironolactone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

2018 Trip Latest and Greatest

3. Spironolactone is effective for treating resistant hypertension

Spironolactone is effective for treating resistant hypertension NIHR DC | Signal - Spironolactone is effective for treating resistant hypertension Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Spironolactone is effective for treating resistant hypertension Published on 1 December 2015 This trial investigated which drug is best added to high blood pressure (hypertension) treatment if blood pressure has not come down to normal levels after taking three blood pressure lowering (...) drugs. Such “resistant hypertension” accounts for around 10% of all people who have hypertension. The study found that adding spironolactone to the existing three-drug regimen was the most effective treatment and was well-tolerated by patients. Spironolactone is currently recommended by NICE at this fourth stage of treatment, but at half the dose used in this study. The higher dose will increase the cost of prescribing slightly. Potassium levels need to be monitored when using spironolactone

2018 NIHR Dissemination Centre

4. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial (PubMed)

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial 28700781 2018 11 13 2380-6591 2 9 2017 Sep 01 JAMA cardiology JAMA Cardiol Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. 950-958 10.1001/jamacardio.2017.2198 Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion (...) , overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF. To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone. This double-blind and placebo (or low-dose)-controlled randomized clinical trial was conducted in 22 US acute care hospitals among patients with AHF who were previously receiving no or low-dose (12.5 mg or 25 mg daily) spironolactone and had NT

Full Text available with Trip Pro

2017 JAMA cardiology

5. [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. (PubMed)

[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. 26948046 2017 08 08 2018 12 02 1578-8865 42 7 2016 10 Semergen Semergen [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. e108-e109 S1138-3593(16)00049-6 10.1016/j.semerg.2016.01.017 Divisón Garrote J A JA Atención Primaria, Centro de Salud Casas Ibáñez, Casas-Ibáñez, Albacete, España (...) ; Universidad Católica San Antonio de Murcia, Murcia, España. Electronic address: jadivison@telefonica.net. Escobar Cervantes C C Servicio de Cardiología, Hospital La Paz, Madrid, España. spa Journal Article Comment Espironolactona versus placebo, bisoprolol y doxazosina para determinar el tratamiento óptimo de hipertensión resistente a fármacos. 2016 03 03 Spain Semergen 9610769 1138-3593 0 Antihypertensive Agents 27O7W4T232 Spironolactone NW1291F1W8 Doxazosin Y41JS2NL6U Bisoprolol IM Lancet. 2015 Nov

2017 Semergen

6. Combined low-dose spironolactone plus vitamin E vs. vitamin E monotherapy on insulin resistance, noninvasive indices of steatosis and fibrosis and adipokine levels in nonalcoholic fatty liver disease: A randomized controlled trial

Combined low-dose spironolactone plus vitamin E vs. vitamin E monotherapy on insulin resistance, noninvasive indices of steatosis and fibrosis and adipokine levels in nonalcoholic fatty liver disease: A randomized controlled trial 28452101 2017 04 28 2017 07 10 1463-1326 2017 Apr 28 Diabetes, obesity & metabolism Diabetes Obes Metab Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and (...) adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. 10.1111/dom.12989 The beneficial effects of mineralocorticoid receptor blockade by spironolactone have been shown in animal models of non-alcoholic fatty liver disease (NAFLD). The aim of the present 52-week randomized controlled trial was to compare the effects of low-dose spironolactone and vitamin E combination with those of vitamin E monotherapy on insulin resistance, non-invasive indices of hepatic steatosis

2017 EvidenceUpdates

7. Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction

Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction 28542926 2017 05 25 2017 05 25 1532-5415 2017 May 19 Journal of the American Geriatrics Society J Am Geriatr Soc Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction. 10.1111/jgs.14940 To evaluate the effects of an aldosterone antagonist on exercise intolerance in older adults (...) with heart failure and preserved ejection fraction (HFpEF). Randomized, placebo-controlled, double-blind trial. Academic medical center, Winston-Salem, North Carolina. Older adults (N = 80, aged 71 ± 1; 80% female) with stable compensated HFpEF and controlled blood pressure (BP). Participants were randomized into a 9-month treatment of spironolactone 25 mg/d vs placebo. Assessments were peak exercise oxygen consumption (VO2 ), 6-minute walk test, Minnesota Living with Heart Failure Questionnaire (MLHFQ

2017 EvidenceUpdates

8. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients (PubMed)

Spironolactone for the treatment of acne in women, a retrospective study of 110 patients 28560306 2018 11 13 2352-6475 3 2 2017 Jun International journal of women's dermatology Int J Womens Dermatol Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. 111-115 10.1016/j.ijwd.2016.12.002 There is limited evidence on the safety and efficacy of spironolactone in the treatment of women with acne. Thus, for many dermatologists spironolactone remains an alternative (...) rather than a mainstay treatment for female patients with acne. An electronic medical records search tool was used to select data from a group of women who received spironolactone to treat acne and were evaluated with the comprehensive acne severity scale (CASS) before treatment and at all follow-up visits. Data points were collected for CASS scores at each follow-up visit, concurrent and previous treatments, and side effects. These data points were used to draw conclusions about the safety

Full Text available with Trip Pro

2017 International journal of women's dermatology

9. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 From: Published: 13 December 2016 (...) Therapeutic area: and In light of feedback, we have clarified our article on concomitant use of these medicines in heart failure. In February 2016, we published an article about the use of spironolactone and renin-angiotensin system drugs in patients with heart failure. Following publication, we received feedback from a small number of readers and a professional organisation that the article was inconsistent with clinical guidelines. We sought advice from the , who considered that the advice outlined

2017 MHRA Drug Safety Update

10. Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension?

Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension? Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension? | Clinical Correlations Gamechanger? Is Spironolactone the Magic Bullet for Resistant Hypertension? November 9, 2016 By Amar Parikh, MD Peer Reviewed Welcome to Gamechangers, a series that takes a critical look at the latest in medical literature to answer one important question: would the results of this article change my practice? Featuring (...) is already on maximum doses of a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEi), and a thiazide-like diuretic, and he refuses any beta blocker as he fears it will worsen his erectile dysfunction. What are your options for additional anti-hypertensives, and would you consider spironolactone? Why Does This Matter? Resistant hypertension (rHTN), defined as suboptimal blood pressure control despite treatment with at least three anti-hypertensives including a thiazide

2016 Clinical Correlations

11. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. (PubMed)

ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. 26882301 2016 06 14 2018 12 02 1539-3704 164 4 2016 Feb 16 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. JC16 10.7326/ACPJC-2016-164-4-016 Rosenberg Mark M Stephens Elizabeth E eng Journal Article Comment United States Ann Intern (...) Med 0372351 0003-4819 0 Adrenergic alpha-1 Receptor Antagonists 0 Adrenergic beta-1 Receptor Antagonists 0 Mineralocorticoid Receptor Antagonists 27O7W4T232 Spironolactone NW1291F1W8 Doxazosin Y41JS2NL6U Bisoprolol AIM IM Lancet. 2015 Nov 21;386(10008):2059-68 26414968 Adrenergic alpha-1 Receptor Antagonists therapeutic use Adrenergic beta-1 Receptor Antagonists therapeutic use Bisoprolol therapeutic use Doxazosin therapeutic use Female Humans Hypertension drug therapy Male Mineralocorticoid

2016 Annals of Internal Medicine

12. Low-dose Spironolactone: Treatment for Osteoarthritis-related Knee Effusion. A Prospective Clinical and Sonographic-based Study (PubMed)

Low-dose Spironolactone: Treatment for Osteoarthritis-related Knee Effusion. A Prospective Clinical and Sonographic-based Study 27036390 2016 06 02 2016 06 02 0315-162X 43 6 2016 Jun The Journal of rheumatology J. Rheumatol. Low-dose Spironolactone: Treatment for Osteoarthritis-related Knee Effusion. A Prospective Clinical and Sonographic-based Study. 1114-20 10.3899/jrheum.151200 To evaluate the effectiveness of spironolactone as a treatment for osteoarthritis (OA)-related knee effusion (...) in comparison to ibuprofen, cold compresses, and placebo. This study was carried out on 200 patients, aged 40 years or older, attending the outpatient clinic of the Rheumatology Department of Sohag University Hospital with unilateral knee effusion related to OA based on clinical examination, musculoskeletal ultrasonography (US), and synovial fluid analysis. In group 1, 50 patients received spironolactone 25 mg daily for 2 weeks; in group 2, 50 patients took ibuprofen 1200 mg daily for 2 weeks; in group 3

2016 EvidenceUpdates

13. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article From: Published: 17 February 2016 Last updated: 14 December 2016 (...) , Therapeutic area: and Monitoring of blood electrolytes is essential in patients coprescribed a potassium-sparing diuretic and an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) for heart failure. Contents Reminder for healthcare professionals: concomitant use of spironolactone with ACEi or ARB increases the risk of severe hyperkalaemia, particularly in patients with marked renal impairment, and should be used with caution use the lowest effective doses

2016 MHRA Drug Safety Update

14. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone (PubMed)

Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone 25646289 2015 03 03 2015 06 18 2017 02 20 1488-2329 187 4 2015 Mar 03 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. E138-43 10.1503/cmaj.140816 Trimethoprim-sulfamethoxazole increases the risk of hyperkalemia when used with spironolactone. We examined whether (...) this drug combination is associated with an increased risk of sudden death, a consequence of severe hyperkalemia. We conducted a population-based nested case-control study involving Ontario residents aged 66 years or older who received spironolactone between Apr. 1, 1994, and Dec. 31, 2011. Within this group, we identified cases as patients who died of sudden death within 14 days after receiving a prescription for trimethoprim-sulfamethoxazole or one of the other study antibiotics (amoxicillin

Full Text available with Trip Pro

2015 EvidenceUpdates

15. Spironolactone for heart failure with preserved ejection fraction. (PubMed)

Spironolactone for heart failure with preserved ejection fraction. 24716680 2014 04 10 2014 04 18 2014 12 09 1533-4406 370 15 2014 Apr 10 The New England journal of medicine N. Engl. J. Med. Spironolactone for heart failure with preserved ejection fraction. 1383-92 10.1056/NEJMoa1313731 Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart (...) failure and a preserved left ventricular ejection fraction. In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo. The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722

2014 NEJM

16. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. (PubMed)

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. 23443441 2013 02 27 2013 02 28 2016 10 17 1538-3598 309 8 2013 Feb 27 JAMA JAMA Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. 781-91 10.1001/jama.2013.905 Diastolic heart failure (ie, heart (...) failure with preserved ejection fraction) is a common condition without established therapy, and aldosterone stimulation may contribute to its progression. To assess the efficacy and safety of long-term aldosterone receptor blockade in heart failure with preserved ejection fraction. The primary objective was to determine whether spironolactone is superior to placebo in improving diastolic function and maximal exercise capacity in patients with heart failure with preserved ejection fraction. The Aldo-DHF

Full Text available with Trip Pro

2013 JAMA

17. Case control: Exposure to trimethoprim?sulfamethoxazole is associated with hospitalisation for hyperkalaemia in older people treated with spironolactone

Case control: Exposure to trimethoprim?sulfamethoxazole is associated with hospitalisation for hyperkalaemia in older people treated with spironolactone Exposure to trimethoprim–sulfamethoxazole is associated with hospitalisation for hyperkalaemia in older people treated with spironolactone | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Exposure to trimethoprim–sulfamethoxazole is associated with hospitalisation for hyperkalaemia in older people treated with spironolactone Article Text Harm Case control Exposure to trimethoprim–sulfamethoxazole

2012 Evidence-Based Medicine (Requires free registration)

18. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. (PubMed)

Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. OBJECTIVES: To characterise the risk of admission to hospital for hyperkalaemia in elderly patients treated with trimethoprim-sulfamethoxazole in combination with spironolactone. DESIGN: Population based nested case-control study. SETTING: Ontario, Canada, from 1 April 1992 to 1 March 2010. PARTICIPANTS: Cases were residents of Ontario aged 66 years or above receiving (...) chronic treatment with spironolactone and admitted to hospital with hyperkalaemia within 14 days of receiving a prescription for either trimethoprim-sulfamethoxazole, amoxicillin, norfloxacin, or nitrofurantoin. Up to four controls for each case were identified from the same cohort, matched on age, sex, and presence or absence of chronic kidney disease and diabetes, and required to have received one of the study antibiotics within 14 days before the case's index date. MAIN OUTCOME MEASURES: Odds ratio

Full Text available with Trip Pro

2011 BMJ

19. Spironolactone attenuates oxidative stress in patients with chronic kidney disease. (PubMed)

Spironolactone attenuates oxidative stress in patients with chronic kidney disease. 18824658 2008 11 13 2018 12 01 1524-4563 52 5 2008 Nov Hypertension (Dallas, Tex. : 1979) Hypertension Spironolactone attenuates oxidative stress in patients with chronic kidney disease. e132-3; author reply e134 10.1161/HYPERTENSIONAHA.108.120568 Renke Marcin M Tylicki Leszek L Knap Narcyz N Rutkowski Przemyslaw P Neuwelt Alexander A Larczynski Wojciech W Wozniak Michal M Rutkowski Boleslaw B eng Letter (...) Randomized Controlled Trial Research Support, Non-U.S. Gov't Comment 2008 09 29 United States Hypertension 7906255 0194-911X 0 Angiotensin II Type 1 Receptor Blockers 0 Angiotensin-Converting Enzyme Inhibitors 0 Antioxidants 0 Benzimidazoles 0 Benzoates 0 Diuretics 0 Mineralocorticoid Receptor Antagonists 0J48LPH2TH Hydrochlorothiazide 19KW7PI29F Cilazapril 27415-26-5 8-epi-prostaglandin F2alpha 27O7W4T232 Spironolactone AYI8EX34EU Creatinine B7IN85G1HY Dinoprost U5SYW473RQ Telmisartan IM Hypertension

Full Text available with Trip Pro

2008 Hypertension (Dallas, Tex. : 1979)

20. Spironolactone and risk of upper gastrointestinal events: population based case-control study. (PubMed)

Spironolactone and risk of upper gastrointestinal events: population based case-control study. OBJECTIVE: To confirm and quantify any association between spironolactone and upper gastrointestinal bleeding and ulcers. DESIGN: Population based case-control study. SETTING: A primary care information database in the Netherlands. PARTICIPANTS: All people on the database who were aged 18 or more between 1 January 1996 and 30 September 2003. Patients with a history of alcoholism or gastrointestinal (...) to 5230 controls. Current use of spironolactone was associated with a 2.7-fold (95% confidence interval 1.2 to 6.0) increased risk of a gastrointestinal event. CONCLUSION: The risk of gastroduodenal ulcers or upper gastrointestinal bleeding is significantly increased in patients using spironolactone.

Full Text available with Trip Pro

2006 BMJ